Dafna Capital Management LLC: 13F holdings, Q2 2026
Hedge fund · SEC EDGAR filings (CIK 1389933) · Explore on the interactive board
Dafna Capital Management LLC disclosed 88 US equity positions worth $524.4m in its Q2 2026 13F filing (holdings as of June 30, 2026, filed August 14, 2026). Its largest position is RVMD at 20.1% of the reported book, followed by XBI, CMPS. The top ten holdings are 56.2% of the book, and the portfolio behaves like about 16 equal-weight positions. Versus the prior filing it opened 17 new positions, added to 17, reduced 25 and exited 12. Note: this manager's most recent filing is 3934 quarters behind the newest quarter on file, so these figures are history rather than current positioning.
What does Dafna Capital Management LLC own? Top holdings as of June 30, 2026
Change is measured in shares against the previous filing (Q1 2026), so price moves do not read as decisions. This quarter: 17 new, 17 added, 25 reduced, 12 exited.
| # | Stock | Sector | Weight | Value | Shares | Δ shares | Action |
|---|---|---|---|---|---|---|---|
| 1 | RVMD REVOLUTION MEDICINES INC | Healthcare | 20.1% | $105.4m | 562,630 | -3% | reduced |
| 2 | XBI SPDR S&P BIOTECH ETF | 5.9% | $31.1m | 196,505 | -38% | reduced | |
| 3 | CMPS COMPASS PATHWAYS PLC | Healthcare | 5.4% | $28.5m | 2,011,952 | -17% | reduced |
| 4 | STXS STEREOTAXIS INC | 4.5% | $23.5m | 13,680,554 | 0% | held | |
| 5 | NKTR NEKTAR THERAPEUTICS | Healthcare | 4.2% | $22.2m | 318,380 | 93% | added |
| 6 | DNLI DENALI THERAPEUTICS INC | Healthcare | 3.6% | $19.0m | 739,014 | 132% | added |
| 7 | IDYA IDEAYA BIOSCIENCES INC | Healthcare | 3.5% | $18.5m | 497,240 | 4% | added |
| 8 | ATRC ATRICURE INC | Healthcare | 3.2% | $16.7m | 597,431 | 0% | held |
| 9 | XENE XENON PHARMACEUTICALS INC | Healthcare | 2.9% | $15.1m | 250,772 | 0% | held |
| 10 | CYTK CYTOKINETICS INC | Healthcare | 2.8% | $14.7m | 171,998 | -21% | reduced |
| 11 | RCUS ARCUS BIOSCIENCES INC | Healthcare | 2.6% | $13.6m | 441,829 | -0% | held |
| 12 | ASND ASCENDIS PHARMA A/S | Healthcare | 2.5% | $12.9m | 48,469 | – | new |
| 13 | NBIX NEUROCRINE BIOSCIENCES INC | Healthcare | 1.9% | $9.7m | 57,769 | -18% | reduced |
| 14 | AXGN AXOGEN INC | Healthcare | 1.8% | $9.7m | 208,960 | -16% | reduced |
| 15 | PODD INSULET CORP | Healthcare | 1.8% | $9.4m | 61,870 | 469% | added |
| 16 | EWTX EDGEWISE THERAPEUTICS INC | Healthcare | 1.8% | $9.2m | 226,819 | 102% | added |
| 17 | BCAX BICARA THERAPEUTICS INC | Healthcare | 1.6% | $8.5m | 284,955 | -32% | reduced |
| 18 | IBB ISHARES NASDAQ BIOTECH INDX | 1.5% | $8.1m | 42,595 | -31% | reduced | |
| 19 | SNDX SYNDAX PHARMACEUTICALS INC | Healthcare | 1.4% | $7.3m | 335,255 | 54% | added |
| 20 | MPLT MAPLIGHT THERAPEUTICS INC | 1.2% | $6.1m | 171,006 | 0% | held | |
| 21 | LRMR LARIMAR THERAPEUTICS INC | Healthcare | 1.2% | $6.1m | 2,008,164 | -1% | reduced |
| 22 | IPSC CENTURY THERAPEUTICS INC | Healthcare | 1.1% | $5.9m | 2,400,458 | -1% | reduced |
| 23 | DXCM DEXCOM INC | Healthcare | 1.1% | $5.8m | 86,279 | 0% | held |
| 24 | IMVT IMMUNOVANT INC | Healthcare | 1.1% | $5.8m | 149,524 | -1% | reduced |
| 25 | INGN INOGEN INC | Healthcare | 1.0% | $5.5m | 845,179 | 0% | held |
| 26 | TNDM TANDEM DIABETES CARE INC | Healthcare | 1.0% | $5.4m | 355,208 | 0% | held |
| 27 | ALKS ALKERMES PLC | Healthcare | 1.0% | $5.3m | 101,266 | -27% | reduced |
| 28 | STOK STOKE THERAPEUTICS INC | Healthcare | 0.8% | $4.3m | 130,875 | 0% | held |
| 29 | ALLO ALLOGENE THERAPEUTICS INC | Healthcare | 0.8% | $4.2m | 2,000,000 | 46% | added |
| 30 | BCRX BIOCRYST PHARMACEUTICALS INC | Healthcare | 0.8% | $4.0m | 400,248 | -7% | reduced |
| 31 | LKFT LAKEFRONT BIOTHERAPEUTICS NV | Healthcare | 0.7% | $3.9m | 130,175 | 0% | held |
| 32 | KIDS ORTHOPEDIATRICS CORP | Healthcare | 0.7% | $3.6m | 189,130 | 98% | added |
| 33 | HELP CYBIN INC | 0.6% | $3.4m | 514,061 | 3% | added | |
| 34 | RAPP RAPPORT THERAPEUTICS INC | 0.6% | $3.1m | 75,000 | 0% | held | |
| 35 | KYMR KYMERA THERAPEUTICS INC | Healthcare | 0.6% | $3.1m | 27,000 | – | new |
| 36 | PROQR THERAPEUTICS NV | 0.5% | $2.8m | 1,530,361 | -2% | reduced | |
| 37 | NGNE NEUROGENE INC | 0.5% | $2.8m | 89,032 | 57% | added | |
| 38 | ANL ADLAI NORTYE LTD | 0.5% | $2.8m | 239,553 | – | new | |
| 39 | PRCT PROCEPT BIOROBOTICS CORP | Healthcare | 0.5% | $2.7m | 120,000 | 0% | held |
| 40 | AQST AQUESTIVE THERAPEUTICS INC | 0.5% | $2.7m | 645,915 | 75% | added | |
| 41 | CLDX CELLDEX THERAPEUTICS INC | Healthcare | 0.5% | $2.5m | 68,518 | 0% | held |
| 42 | GPCR STRUCTURE THERAPEUTICS INC | Healthcare | 0.5% | $2.5m | 46,500 | 0% | held |
| 43 | ALGN ALIGN TECHNOLOGY INC | Healthcare | 0.5% | $2.4m | 14,000 | -7% | reduced |
| 44 | VKTX VIKING THERAPEUTICS INC | Healthcare | 0.4% | $2.3m | 59,516 | 0% | held |
| 45 | NERVGEN PHARMA CORP | 0.4% | $2.2m | 1,050,000 | – | new | |
| 46 | BHVN BIOHAVEN LTD | Healthcare | 0.4% | $2.0m | 137,593 | -84% | reduced |
| 47 | MAZE MAZE THERAPEUTICS INC | Healthcare | 0.4% | $1.9m | 65,000 | 86% | added |
| 48 | ALEC ALECTOR INC | Healthcare | 0.3% | $1.8m | 908,351 | 0% | held |
| 49 | LXEO LEXEO THERAPEUTICS INC | Healthcare | 0.3% | $1.8m | 377,059 | 0% | held |
| 50 | PROF PROFOUND MEDICAL CORP | 0.3% | $1.7m | 260,360 | -1% | reduced |
What did Dafna Capital Management LLC sell? Positions exited since the previous filing
| Stock | Prior weight | Prior value |
|---|---|---|
| DAWNGBX DAY ONE BIOPHARMACEUTICALS I | 47.4% | $21.0m |
| ASND ASCENDIS PHARMA A/S | 13.4% | $5.9m |
| 4XC1 KALVISTA PHARMACEUTICALS INC | 12.2% | $5.4m |
| ASND ASCENDIS PHARMA A/S | 12.0% | $5.3m |
| FULC FULCRUM THERAPEUTICS INC | 3.6% | $1.6m |
| ENGENE HOLDINGS INC | 2.9% | $1.3m |
| SCYX SCYNEXIS INC | 2.3% | $996.6k |
| ORIC ORIC PHARMACEUTICALS INC | 2.1% | $945.5k |
| ZBIO ZENAS BIOPHARMA INC | 1.9% | $830.9k |
| NEWAMSTERDAM PHARMA CO | 1.4% | $640.2k |
| KPTI KARYOPHARM THERAPEUTICS INC | 0.6% | $255.1k |
| NMRA NEUMORA THERAPEUTICS INC | 0.3% | $136.5k |
Sector mix
| Sector | Weight |
|---|---|
| Healthcare | 80.8% |
Sectors cover positions whose ticker resolved to a sector; the remainder is unclassified, not cash.
Filing history
How concentrated is Dafna Capital Management LLC's portfolio?
Across every quarter Dafna Capital Management LLC has filed, its median largest position is 16.5% of the book and its median top-ten weight is 54.3%, which WhaleCreep classifies as concentrated (the gate is a median largest position of 5%). Of 9.0 completed holding spells, the median lasted 1.0 quarters; 88.0 positions are still open and their final length is unknown.